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Abstract
Background/Aims: The two-pore-domain potassium channel TASK-1 regulates atrial action 
potential duration. Due to the atrium-specific expression of TASK-1 in the human heart and 
the functional upregulation of TASK-1 currents in atrial fibrillation (AF), TASK-1 represents a 
promising target for the treatment of AF. Therefore, detailed knowledge of the molecular 
determinants of TASK-1 inhibition may help to identify new drugs for the future therapy of 
AF. In the current study, the molecular determinants of TASK-1 inhibition by the potent and 
antiarrhythmic compound A293 (AVE1231) were studied in detail. Methods: Alanine-scanning 
mutagenesis together with two-electrode voltage-clamp recordings were combined with in 
silico docking experiments. Results: Here, we have identified Q126 located in the M2 segment 
together with L239 and N240 of the M4 segment as amino acids essential for the A293-
mediated inhibition of TASK-1. These data indicate a binding site which is different to that of 
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A1899 for which also residues of the pore signature sequence and the late M4 segments are 
essential. Using in silico docking experiments, we propose a binding site at the lower end of 
the cytosolic pore, located at the entry to lateral side fenestrations of TASK-1. Strikingly, TASK-
1 inhibition by the low affinity antiarrhythmic TASK-1 blockers propafenone, amiodarone and 
carvedilol was also strongly diminished by mutations at this novel binding site. Conclusion: 
We have identified the A293 binding site in the central cavity of TASK-1 and propose that this 
site might represent a conserved site of action for many low affinity antiarrhythmic TASK-1 
blockers.
IntroductionThe family of two-pore-domain potassium (K2P) channels is the last identified among 
potassium channels. The 15 members of this heterologous group share a unique structure of 
four membrane spanning domains and the eponymous two pore-forming loops per subunit [1]. Assembled as homo- or heterodimers, most K2P channels conduct quasi-instantaneous, 
non-inactivating background potassium currents that modulate cellular excitability [2, 3]. K2P 
channels are regulated by a wide variety of physiological stimuli, including polyunsaturated 
fatty acids, mechanical stress, heat, pH level and pharmacologic agents [4]. Therefore, K2P 
currents contribute to regulation of a large variety of physiological functions, including 
regulation of cardiac rhythm, blood pressure, exocrine secretion, sensation of oxygen tension, taste and temperature [5-9] Additionally, they are implicated in neuroprotection, anesthesia, 
apoptosis and carcinogenesis [10].In the heart K2P3.1 (TASK-1, tandem of P domains in a weak inward rectifying K+ channel (TWIK)-related acid sensitive K+ channel 1) K+ currents contribute to the delayed rectifier sustained outward current IKsus [11] observed in mouse cardiomyocytes or the plateau current IKP [12], described in cardiomyocytes from guinea pig [13, 14]. In the human heart, 
TASK-1 channels display virtually atrial specific expression [14] and inhibition of TASK-1 
was shown to prolong action potential duration of atrial cardiomyocytes [14, 15]. Moreover, 
we could recently demonstrate that TASK-1 currents alter atrial action potential duration in 
patients suffering from atrial fibrillation (AF) or heart failure (HF) [15, 16].
AF is the most common sustained arrhythmia in clinical practice, constituting one 
of the major causes of stroke, acute HF, and cardiovascular morbidity [17]. Despite its 
epidemiological and individual relevance, safe and effective management of AF remains an 
unmet medical need as current pharmacological, interventional or surgical therapy strategies are limited by suboptimal effectiveness and not uncommonly by severe adverse effects [18]. 
Accordingly, there is a high medical need for novel drugs targeting AF.
Due to the very low ventricular expression levels of TASK-1 and the fact that TASK-1 
inhibition prolonged human atrial action potential duration, TASK-1 currents represent a 
promising drug target for the treatment of AF [14]. This conclusion is further strengthened 
by recent observations, that in patients suffering from AF, TASK-1 currents are upregulated 
[15, 19], potentiating antiarrhythmic effects of a TASK-1 blockade. Additionally, a general 
role for TASK-1 channels as antiarrhythmic drug targets is supported by their sensitivity 
to clinically used antiarrhythmic agents like amiodarone, carvedilol, digoxin, dronedarone, 
mexiletine and propafenone when administered in supratherapeutic concentrations [9, 20-
22]. Molecular mechanisms of these interactions however remain far from clear. Until today 
only a few potent TASK-1 inhibitors are available.
However, first studies were already successfully exploring the role of TASK-1 channels 
utilizing these blockers, A293 and A1899, for isolation of native TASK-1 currents. Initially these compounds were developed as KV1.5 inhibitors by Sanofi-Aventis (Frankfurt, Germany), 
these experimental antiarrhythmic drugs later turned out to be much more potent TASK-1 
inhibitors active in the nanomolar range [23]. Recently, the bis-amide ML365 was proposed 
as a further high affinity inhibitor of TASK-1 [24].
© 2019 The Author(s). Published by 
Cell Physiol Biochem Press GmbH&Co. KG
Cell Physiol Biochem 2019;52:1223-1235
DOI: 10.33594/000000083
Published online: 19 April 2019 1225
Cellular Physiology 
and Biochemistry
© 2019 The Author(s). Published by 
Cell Physiol Biochem Press GmbH&Co. KG
Wiedmann et al.: TASK-1 Drug Binding Site of A293
A comprehensive analysis revealed a distinct set of amino acids that line the inner 
pore of TASK-1 to contribute to the block caused by A1899 (S20951) [25]. Whether these 
amino acids mediate TASK-1 interaction with other high affinity (e.g. A293, ML365) or low 
affinity blockers of TASK-1 remained unclear. Thus, we aimed to characterize the molecular 
interaction site of the potent blocker A293 with TASK-1 channels and to assess whether this 
drug binding site is also responsible for interactions with low affinity TASK-1 inhibitors like commonly used antiarrhythmic compounds.
Materials and Methods
Molecular Biology
Complementary DNAs encoding hK2P3.1 (NM_002246) subcloned in the pRAT backbone (a dual purpose 
expression vector for in vitro RNA transcription and CMV promoter mediated expression in mammalian 
cells) were kindly provided by Steve Goldstein (Loyola University, Chicago, Il, USA). Alanine mutants of pRAT-
TASK-1 were generated by site-directed mutagenesis, using the QuickChange II system (Agilent, Santa Clara, 
CA, USA), according to the manufacturer’s instructions. Coding sequences of all constructs were completely 
sequenced (GATC-Biotech, Konstanz, Germany). In vitro synthesis of copy RNA was carried out, using the 
mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific Waltham, MA, USA) according to 
the manufacturer’s instructions. Nucleic acid concentration was determined by spectroscopy (ND-1000, 
Thermo Fisher Scientific) and integrity of transcripts was assessed via agarose gel electrophoresis.
Oocyte Preparation
Animal experiments have been carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health (NIH publication 
No. 86-23, revised 1985) and with EU Directive 2010/63/EU, and the current version of the German Law on the Protection of Animals was followed. The manuscript does not contain clinical studies or patient data. 
The investigation conforms to the Directive 2010/63/EU of the European Parliament. Approval was 
granted by the local Animal Welfare Committee (reference number A-38/11). All experiments have been 
carried out in accordance with the United States National Institutes of Health Guide for the Care and Use 
of Laboratory Animals (NIH Publication No. 85–23, revised 1996) as reported earlier in detail [20, 21, 
26]. Oocytes were isolated from Xenopus laevis ovarian lobes after surgical extirpation during tricaine 
anaesthesia (1 g/l; pH 7.5). Complementary RNA (0.75-18 ng; 46 nl/oocyte) was injected into stage V–VI defolliculated Xenopus oocytes.
Electrophysiology
Two-electrode voltage clamp recordings from Xenopus laevis oocytes were performed one to three 
days after cRNA injection as described [27]. Macroscopic currents were measured with an OC-725C 
amplifier (Warner Instruments, Hamden, CT, USA). Electrodes were fabricated from borosilicate glass (GB 
100F-10, Science Products, Hofheim, Germany) using a Flaming/Brown P-87 micropipette puller (Sutter 
Instruments, Novato, CA, USA) and had tip resistances from 1-2 MOhm. All experiments were carried 
out at room temperature (20-22°C) under constant superfusion with extracellular solution by a gravity 
driven perfusion system. Data were filtered through an eight-pole Bessel filter and leak currents were not 
subtracted. The holding potential was -80 mV in all experiments.
Solutions and Drugs
Two-electrode voltage clamp electrodes were filled with 3 M KCl. The standard extracellular solution for 
oocytes recordings contained 96 mM NaCl, 4 mM KCl, 1.1 mM CaCl2, 1 mM MgCl2, 5 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (pH 7.4). The aromatic carbonamide A293 (2-(butylsulfonylamino)-
N-[(1R)-1-(6-methoxy-3-pyridyl) propyl]benzamide) was kindly provided by Sanofi-Aventis (Frankfurt, 
Germany). A 10 mM DMSO stock of A293 was stored at -20°C. Amiodarone, carvedilol and propafenone 
were purchased from Sigma-Aldrich (Munich, Germany) and dissolved in DMSO at concentrations of 
100 mM (-20°C). On the day of experiments, aliquots of the stock solutions were diluted to the desired 
concentrations with standard extracellular solution.
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Molecular modelling
A TASK-1 homology model based on TWIK-1 channel (PDB ID: 3UMK) was used for docking calculations, 
as previously described [28]. The molecular docking calculation was performed using Glide v.7.4 with the 
standard precision (SP) mode [29]. Docking grid was centered on residues that significantly affects the 
conduction of the channel (Q126, L239, N240) and a cubic box with the axial length of 25Å was used. The 
A293 ligand in its neutral state was prepared using LigPrep module (LigPrep, Schrödinger, LLC, New York, 
NY, USA, 2017). Energy minimization in the gas phase using Macromodel (MacroModel, Schrodinger, LLC, 
New York, NY, USA, 2017) with the OPLS2005 force field was performed. Twenty conformers of the ligand 
previously optimized were generated using ConfGen tool [30]. For the poses generation, it was enabled the 
strain correction for the GlideScore. Finally, one hundred poses were generated (five poses per conformer).
Data Analysis, visualization and Statistics
Current amplitudes were measured at the end of the +20 mV test pulse. Data are presented as mean ± 
S.E.M. pClamp9 (Axon Instruments, Foster City, CA, USA) and Prism 5 (GraphPad, La Jolla, CA, USA) software 
was used for data acquisition and analysis. Statistical comparisons were performed using paired and 
unpaired Student´s t tests (two-tailed tests), where appropriate. A P value < 0.05 was considered statistically 
significant. Multiple comparisons were performed using the one-way ANOVA. If the hypothesis of equal 
means could be rejected at the 0.05-level, pair wise comparisons of groups were made and the probability 
values were adjusted for multiple comparisons using the Bonferroni correction. Visualizations of in silico 
simulations and dockings were generated with Pymol 2 (The PyMOL Molecular Graphics System, Version 
2.0 Schrödinger, LLC, New York, NY, USA).
Results
TASK-1 inhibition by A293
Inhibition of TASK-1 (K2P3.1) channels by the aromatic carbonamide A293 (AVE1231) 
(Fig. 1a) was studied after heterologous expression of the channel in Xenopus laevis oocytes. 
24 – 48 h after injection of cRNA encoding human wild-type (WT) TASK-1, potassium 
currents were elicited by voltage steps to potentials ranging from -80 to +60 mV (500 ms), 
applied in +20 mV increments at a frequency of 0.2 Hz. The holding potential was set to -80 
mV and measurements were repeated every 2 minutes. Representative families of TASK-1 
current traces before and after application of 10 µM A293 are depicted in Fig. 1b-c. Upon 
application of 245 nM A293 (20 min) a rapid current decline to 74.1 ± 4.3% (n = 3) of control 
currents was observed (Fig. 1d) and after increasing the blocker concentration to 10 µM (20 
min), relative TASK-1 currents remaining were only 19.3 ± 7.7% (n = 3).
Fig. 1. TASK-1 channel blockade by A293. (a) Chemical structure of the aromatic carbonamide A293. (b-
c) Human TASK-1 channels were heterologously expressed in Xenopus laevis oocytes. Families of TASK-1 
current traces under control conditions (b) and after administration of 10 µM A293 (c). The voltage protocol 
is depicted as inset. (d) Time course of TASK-1 blockade by 240 nM or 10 µM of A293 (n = 3). Data are 
displayed as mean ± S.E.M.
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Identification of the A293 binding site in TASK-1
In previous studies TASK-1 and TASK-3 (K2P9.1) inhibitors were identified to bind at the 
intracellular central channel cavity [25, 31]. TASK-1 amino acids potentially involved in A293 
binding were identified in silico using a TASK-1 homology model, based on the crystal structure of human TWIK-1 (K2P1.1), TREK-1 (K2P2.1) and TRAAK (K2P4.1) channels. Therefore, after 
visualization of the three dimensional channel structure, a set of 45 amino acids that line the intracellular site of the channel pore were individually mutated to alanine and one alanine 
residues was changed to valine (Fig. 2a). As observed previously in potassium channels with 
other domain topologies (for example rKv1.2 and KirBac1.1) these pore lining residues are 
predominantly located at the transmembrane segments following the selectivity filter [32, 
33], corresponding to the M2 and M4 transmembrane domains of TASK-1 [25].
While TASK-1 WT channels were blocked by 10 µM A293 by 80.7 ± 7.7% (n = 3) (Fig. 2b 
and f), we identified three residues that showed significantly reduced blocking efficiencies 
(Fig. 2b-e). In the M2 segment (Fig. 2a and g) we found that TASK-1 Q126A mutant channels 
were only blocked by 45.1 ± 4.8% (p = 0.011, n = 3, Fig. 2c). In the M4 segment (Fig. 2a and j) 
we found reduced A293 inhibition for L239A and N240A. For TASK-1 L239A channels, A293 
effects were reduced with 31.5 ± 1.5% (p = 0.0023, n = 3, Fig. 2d and j) and introduction of 
the N240A mutation yielded channels with a reduction in A293 blockade of 30.3 ± 7.0% 
(p = 0.050, n = 3, Fig. 2e and j). Recording the IC50 values for the mutations that we have 
identified in our alanine-scanning approach, we observed a 42-fold change in IC
50
 for Q126A, 
a 108-fold for L239A and a 78-fold for N240, respectively (Supplementary Table 1 – for all supplemental material see www.cellphysiolbiochem.com).
Q126A, L239A and N240A are part of the A293 binding site
To further support the results of the alanine-scanning mutagenesis, alanine mutations 
identified to contribute to the A293 drug binding site were introduced as double mutations 
in single TASK-1 constructs. Combination of the Q126A/L239A mutations almost completely 
abolished inhibition by A293 (n = 4, Fig. 3b and e). In a similar manner, TASK-1 Q126A/
N240A double mutants displayed only a minor A293-dependent inhibition (n = 5, Fig. 3c and 
e), while the TASK-1 L239A/N240A showed virtually no A293-dependent block at all (n = 
Fig. 2. Alanine-scan to identify the A293 binding site in TASK-1. (a) Amino acids or regions subjected to 
alanine scanning mutagenesis are displayed in different colors for the different domains, f´ for the P1 (pore 
forming loop 1) pore signature sequence, g´ for the M2 (transmembrane domain 2) segment, h´ for the M3 
(transmembrane domain 3) segment, i´ for the P2 (pore forming loop 2) pore signature sequence and j´ for 
the M4 (transmembrane domain 4) segment. A TASK-1 homodimer consisting of only M1, P1 and M2 domains 
where M3, P2 and M4 domains are omitted for clarity is displayed in f ’ and g’. Homodimers of TASK-1 channels 
consisting of only M3, P2 and M4 domains where M1, P1 and M2 domains have been omitted are displayed in 
h’-j’. (b-e) Representative currents of TASK-1 WT and mutant channels before (black) and after the application 
of 10 µM A293 (blue). (f-j) Inhibition of TASK-1 pore mutant channels by 10 µM A293 is displayed, compared 
to TASK-1 WT channels (dashed line). Data are given as mean ± S.E.M.. * p<0.05, *** p<0.001.
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5, Fig. 3d and e). A TWIK-1-based TASK-1 homology model reveals that Q126A, L239A and 
N240A are located at approximately the same height at the lower intracellular end of the 
central channel cavity (Fig. 3f-h). Note that the unrestricted view into the central cavity is 
possible through the large lateral side fenestrations (LF; Fig. 3f-g).
A293 binds to the lower central cavity at the lateral entry to the LF
Next we in silico docked A293 into a TWIK-1-based TASK-1 homology model (Fig. 4). 
We have obtained 100 docking solutions, which include five poses for twenty different 
conformers (see Methods). Overall we only obtained two significant clusters with 19 and 11 
docking solutions, respectively, indicating relatively low variability. Fig. 4a-d illustrate the 
30 docking solutions of these two clusters, highlighting that the docking solutions are highly 
similar. From these docking solutions we have chosen the one that showed (1) interactions 
with all the residues that we have identified, (2) while it is predicted to prevent K+ flux 
through the central cavity (Supplementary Fig. 1a) and (3) having the lowest energy as the 
final docking solution. The best docking solution was obtained for an A293 docking pose for 
which the drug binds at the lower end of the central cavity directly in front of the entry to the 
LF (Fig. 4a,b,e). A293 binds in the central cavity in close proximity (less than 4 Å distance) 
to Q126, L239 and N240 identified in our alanine-scanning mutagenesis (Fig. 4e-h). Here 
Fig. 3. Q126A, L239A and N240A are part of the A293 binding site: illustration in a TASK-1 pore homology 
model. (a-e) TASK-1 channels harboring combined mutations of the A293 binding site (double mutations 
with Q126A, L239A or N240A) show strongly reduced A293 sensitivity. (a-d) Representative current traces 
under control conditions (black) and after superfusion with 10 µM A293 (blue). (e) Analyses of the inhibition 
of Q126A/L239A, Q126A/N240A and L239A/N240A double mutants by 10 µM A293. Data are provided as 
mean ± S.E.M. *** p<0.001 vs. WT. (f-g) TWIK-1-based TASK-1 homology model illustrating the A293 binding 
site at the lower end of the central cavity. (f) Overview illustrating the location of Q126A, L239A and N240A 
in TASK-1 and (g) zoom into the central cavity. (f-g) Note that the view into the central cavity is possible 
through the large lateral side fenestrations. (h) Lateral view as in (g) but from the other side of the channel. The lower panel illustrates the view from inside the cell into the central cavity.
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we identified hydrophobic interactions of the pyridil-group or the butyl side chain of A293 
with Q126 or L239 in TASK-1, as well as a H-bond of the pyridil nitrogen atom of A293 to the 
amide group of N240 (Fig. 4e-h and Supplementary Fig. 2). Note that A293 is located just in 
front of the LF and is able to interact with both L239 residues located within the pathways of 
the fenestrations (Fig. 4a,b,e and Supplementary Fig. 2).
Comparing the drug binding site of high affinity and low affinity TASK-1 inhibitors
In heterologous expression systems, antiarrhythmic drugs block TASK-1 channels when 
applied in supratherapeutic concentrations [9, 20, 21, 22, 26, 34, 35]. To probe whether 
these low affinity TASK-1 inhibitors and the high affinity blocker A293 share a common drug 
binding site, Vaughan Williams class I to III antiarrhythmic drugs were tested for their effects 
on the combined pore alanine mutations. Experiments were conducted using the L239A/
N240A double mutant, as this construct displayed the most robust expression of the double 
mutants we tested, with an almost complete loss of drug sensitivity at 10 µM A293 (Fig. 
3d). Upon administration of the class I anti arrhythmic drug propafenone (100 µM), TASK-1 
WT channels displayed an inhibition of outward potassium currents by 75.4 ± 7.0% (n = 3) 
(Fig. 5a), similar as reported in previous studies [9]. The L239A/N240A double mutation 
however, abolished the inhibitory effects of propafenone at this given concentration (Fig. 5a). 
After 30 min of perfusion with 100 µM propafenone only a -7.9 ± 12.8% (n = 3) increase 
in outward potassium currents was observed, reflecting a strongly reduced propafenone 
inhibition (p = 0.0097, n = 3). Similar observations were made for the class II antiarrhythmic 
drug and beta blocking agent carvedilol that was described to exert TASK-1 blocking effects 
Fig. 4. A293 binds to the lower central cavity at the lateral entry to the side fenestrations. (a-d) A293 
binding modes in a TWIK-1-based TASK-1 homology model. Illustrated are all 30 docking solutions of the 
two significant clusters that we obtained, with 19 and 11 docking solutions, respectively. (a) Bottom view 
of A293 located in the central cavity in close proximity to Q126, L239 and N240. (b) Similar display as 
in (a) illustrating the surface area and the side fenestrations (LF). Note that A293 directly binds in front 
of the entry to the LF, interacting with L239 located in the fenestrations. (c) Zoom into the central cavity 
illustrating the poses of the two significant clusters and the residues that we identified with the alanine 
scanning mutagenesis. (d) Similar zoom-in but view from inside the cell. Note that A293 is able to interact 
with L239 of both fenestrations (distance less than 4 Å). (e) Best docking solution of A293 in the TASK-1 
homology model and zoom-ins to illustrate the interactions of A293 with (f) Q126, (g) the L239 residue of 
both subunits and (h) N240.
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[21]. While carvedilol (100 µM, Fig. 5b) displayed robust inhibition levels on WT TASK-1 
channels (75.7 ± 4.7%, n = 3), double mutant TASK-1 L239A/N240A channels were virtually 
insensitive to carvedilol (-2.7 ± 6.5%, p = 0.00097, Fig. 5b). Finally, the non-specific potassium 
channel blocker class III antiarrhythmic drug amiodarone, reduced WT TASK-1 currents by 
52.3 ± 7.3% (Fig. 5c) comparable to data from earlier studies [20]. In contrast, amiodarone-
induced blockade of TASK-1 L239A/N240A double mutant channels was strongly reduced (p 
= 0.011) and only 1.1 ± 7.7% inhibition remained (n = 3-4, Fig. 5c).
Discussion
Safe and effective treatment of AF still remains an unmet clinical need in cardiovascular 
medicine [18]. To avoid potentially life-threatening proarrhythmic effects in the ventricular 
myocardium, recent research focuses on the identification of atrial specific drug targets 
[28]. While other potassium channels that are predominantly expressed in the human 
atria like Kv1.5 are downregulated in AF-associated electrical remodeling [36] TASK-1 
upregulation might potentiate antiarrhythmic effects of TASK-1 inhibition in AF patients 
[15, 19]. Experimental Kv1.5 channel inhibitors have recently been described to exert 
TASK-1 blocking effects [13, 23, 25] and a number of clinically used antiarrhythmic drugs 
are known to interact with TASK-1 channels at supratherapeutic plasma levels [37]. In this 
context we aimed to assess the molecular determinants of the A293 drug binding site in 
TASK-1 channels. Following in silico identification of TASK-1 inner pore lining amino acid 
residues, alanine-scanning mutagenesis identified the three residues Q126, L239 and N240 
as critical components of the A293 binding site in TASK-1. Combined substitution of two 
of these residues prevented A293 inhibition of TASK-1 almost completely. In silico docking 
simulations of A293 to a homology model of TASK-1 predicted an A293 binding pose, with 
the compound located at the cytosolic end of the central cavity at the opening to the LF. 
Strikingly, the combined site-directed alanine mutagenesis of L239 and N240 residues also 
virtually abolished the apparent affinity of TASK-1 to class I - III antiarrhythmic drugs. Thus, 
high and low affinity antiarrhythmic TASK-1 blockers share overlapping binding sites.
Previously, the drug binding site of the high affinity inhibitor A1899 was revealed for 
TASK-1, using a comparable alanine-scanning approach [25]. The ten amino acids that 
contribute to A1899 binding include the L239-N240 region identified in our study. In 
addition, also the alanine exchange of Q126 was shown to reduce the apparent affinity of 
A1899. Therefore, drug binding sites of high affinity inhibitors A293 and A1899 display some 
overlap. While L122 displayed moderate interaction with A293 in our study, I235, V243 and 
M247 solely contribute to TASK-1 interaction with A1899 and not with A293.
Fig. 5. Overlapping drug binding sites of high and low affinity TASK-1 inhibitors. As previously reported, 
Vaughan Williams class I (propafenone), II (carvedilol) and III (amiodarone) antiarrhythmic drugs display 
strong TASK-1 inhibition when applied in supratherapeutic levels (100 µM). In TASK-1 channels harboring 
a L239A/N240A double mutation effects of propafenone (a), carvedilol (b) and amiodarone (c) are virtually 
abolished. Data are presented as mean plus minus S.E.M.. * p<0.05, ** p<0.01, *** p<0.001.
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Kiper et al. hypothesized that the molecular drug binding sites of TASK-1 and Kv1.5 
may share structural similarities as several Kv1.5 inhibitors show high affinity for TASK-1 
channels [23]. The authors proposed a structure of three rings encircling the ion conduction 
pathway (T93 and T199; I118 and I235 as well as L122 and L239). In their model the 
A293 interaction site would be located at the most intracellular hydrophobic ring leucine 
consisting of L122 and L239. T93, T199 and I118 could not be investigated in our project due 
to lack of functionality and I235 was not involved in A293 binding.
To identify the drug interaction site of closely related TASK-3 channels, Chokshi et al. 
employed a different approach, expressing aspartate mutant channels in fisher rat thyroid 
cell monolayers [31]. The proposed TASK-3 binding site of doxapram includes residues 
L122, and L239 contributing to the A1899 binding site in TASK-1 [25]. This points towards 
conservation of the drug binding site among different members of the TASK subfamily.
When calculating an atomic structural closed state model for the K2P channel TREK-1 
in a membrane environment, Treptow and Klein identified the two leucine residues 174 
and 289, located in the M2 and M4 domains to delimit the narrowest part of the inner pore 
and to form a hydrophobic gate [38]. However, when looking at the recently revealed TREK-
1 crystal structure [39], one can note that it is not L174 but L175 that point towards the 
central cavity. The TREK-1 leucine residues 175 and 289 align to TASK-1 residues Q126 and 
L239, identified as part of the A293 drug binding site in this study.
One major difficulty in designing specific TASK-1 blockers, however, remains the high 
homology of TASK-1 and TASK-3 channels. Out of the 46 pore lining amino acids examined 
in this project, 43 remain conserved among human TASK-1 and TASK-3 channels. From the 
remaining 3 residues L115 and I132 (i.e. V115 and M132, respectively in TASK-3) do not 
contribute to the A293 drug binding site in TASK-1, while I162 (i.e. V162 in TASK-3) showed 
no measurable currents. Therefore, all residues identified to contribute to TASK-1 binding 
of A293 are conserved in TASK-3 channels. This explains the high TASK-3 affinity of A293 
reported by Putzke et al. 2007 [13] and our group [15]. Thus, a specific TASK-1 inhibitor that 
shows no side effects on TASK-3 currents would have to target a different binding site inside 
the TASK-1 channel pore. Whether TASK-1 over TASK-3 specificity has to be accomplished for 
development of a new antiarrhythmic drug remains however uncertain, as TASK-3 channels 
display in some studies low cardiac abundance [15], while other studies report strong 
expression of TASK-3 in human atrial cardiomyocytes and heterodimer formation of TASK-1 
and TASK-3 [40]. Potential limitations of this study arise from the fact that only functionally 
active mutant channels were accessible for our investigations. Therefore, contribution of non-
functional TASK-1 mutant channels I91A, T93A, I118A, N133A, I162A, L171A, F194A, T199A 
and V234A to the A293 binding site remains unclear. Unfortunately, the alanine mutation at 
I118 which is one of the most important residues involved in the binding site of A1899, did 
not express in the framework of the current study. We have already previously noted [25] 
that the I118A mutant is very poorly expressing. However, consistent with the previously 
identified role of I118 in drug binding, this residue might be also relevant for the interaction 
with A293, as it is within less than 4 Å to the butyl group of A293 (Supplementary Fig. 1b). 
Furthermore, changes in apparent binding affinity were not directly monitor as it could be 
performed with for example a radioligand binding assay. However, also binding assays would 
have their limitations as binding does not necessarily indicate inhibition, meaning that the 
inhibition can be abolished by a mutation while the drug still binds.
Clinical implications
Emerging evidence suggests a major role of TASK-1 currents in pathogenesis of AF. 
Better knowledge of the molecular determinants of different drug binding sites in TASK-1 
might finally advance the development of more potent and specific TASK-1 inhibitors. Novel 
specific TASK-1 blockers would be of great use in basic research and furthermore represent 
lead structures for development of new antiarrhythmic agents. However, it remains 
speculative whether differences in the specific drug binding site might result in different 
antiarrhythmic potency of TASK-1 inhibitors.
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Conclusion
In conclusion, we have mapped the residues in the central cavity of TASK-1 that interact 
with A293 and mediate the inhibition of TASK-1. Furthermore, substitution of these residues 
with alanine also reduced the apparent affinity of low affinity inhibitors of the TASK-1 
channels like antiarrhythmic drugs. The inferred TASK-1 drug binding site of A293 partially 
overlaps with the site previously described for A1899 a high affinity inhibitor of TASK-1 [25] 
and the proposed TASK-3 binding site of doxapram [31]. Further studies will show whether 
differences in the molecular binding site of TASK-1 blockers affect antiarrhythmic potency 
of TASK-1 inhibitors.
Abbreviations
A (alanine); A293 (2-(butylsulfonylamino)-N-[(1R)-1-(6-methoxy-3-pyridyl)propyl]
benz amide); AF (atrial fibrillation); HF (heart failure); K2P (two-pore-domain); TASK-1 ((TWIK)-related acid sensitive K+ channel 1); TASK-3 ((TWIK)-related acid sensitive K+ 
channel 3); TRAAK (TWIK-related arachidonic acid-stimulated K+ channel); TREK-1 (TWIK-related K+ channel 1); TWIK-1 (tandem of P domains in a weak inward rectifying K+ channel); WT (wild type).
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